Tericin AT, a vaginal cream combining amphotericin B and tetracycline, has demonstrated significant clinical efficacy in treating vulvovaginitis and colpitis. Research indicates high cure rates for mixed infections involving Candida and Trichomonas, with studies showing clinical and bacteriological success in as many as 87.5% of patients.
The dual-action mechanism of Tericin AT addresses the complex nature of vaginal infections. Amphotericin B functions as an antifungal agent by binding to ergosterol, a primary component of fungal cell membranes, which creates pores that lead to cell death. Tetracycline acts as an antibacterial agent by inhibiting protein synthesis within the bacteria. This combination allows the cream to target both fungal and bacterial pathogens in a single application.
Clinical Success Rates Across Medical Studies
Clinical evaluations of Tericin AT have yielded varying results depending on the specific pathogen and the duration of the treatment regimen. According to data regarding the clinical efficacy of Tericin AT, researchers have tracked significant improvements in women suffering from mixed infections involving C. albicans and other agents, including Enterococcus, Haemophilus vaginalis, and Staphylococcus aureus.
In a study conducted by Patrono et al. involving 35 women, researchers divided participants into two distinct treatment groups. The first group, receiving one daily application for 7 to 10 days, achieved an 87.5% clinical and bacteriological cure rate after the first cycle. The second group, which utilized two daily applications over 7 days, showed an 81.8% cure rate after the first cycle.
Other research has focused on specific types of vaginitis. A study by Moreto et Villani examined 28 patients with candidiasis and 32 with trichomoniasis. For the candidiasis group, the total cure rate reached 72% when combining the first and second treatment cycles. The trichomoniasis group saw a total cure rate of 69%.
| Study Group | Condition | Reported Cure Rate |
|---|---|---|
| Patrono et al. (Group 1) | Mixed Infection | 87.5% (1st cycle) |
| Moreto et Villani | Candidiasis | 72% (Total) |
| Moreto et Villani | Trichomoniasis | 69% (Total) |
| Rubin et al. (Group 2) | Leucorrhea | 86% (4-day scheme) |
| End of Table | ||
In the context of these studies, a distinction is made between clinical and bacteriological success. Clinical success refers to the resolution of physical symptoms, such as itching or abnormal discharge. Bacteriological success indicates that the pathogen has been eliminated from the site, as confirmed by laboratory analysis. While the reported success rates are high, these findings are based on specific study populations and individual results may vary depending on the severity and type of the infection.
Further analysis by Rubin et al. investigated patients presenting with leucorrhea. Their findings suggested that a shorter, four-day treatment scheme was highly effective, resulting in an 86% cure rate among the 39 patients studied.
Indications for Vulvovaginitis and Post-Cauterization
The medication is primarily utilized for the treatment of vulvovaginites and colpites caused by fungi, bacteria, or Trichomonas. It is also prescribed when the specific etiological agent cannot be identified. When a physician prescribes medication because a specific etiological agent is unknown, they are utilizing empirical therapy. This is a common clinical practice used to treat suspected infections while awaiting laboratory culture results or when the patient presents with symptoms consistent with multiple types of pathogens.
Beyond infection control, the cream is used following the cauterization of the cervix to prevent infection and accelerate the healing process. Following cervical procedures such as cauterization, the mucosal tissue is in a sensitive state of recovery. The application of an antimicrobial cream in this period serves to prevent secondary infections from opportunistic bacteria or fungi, thereby supporting the natural healing of the cervix.
Medical reports note that genital candidiasis occurs with increased frequency during pregnancy. It is also more common following the use of antibiotic or corticosteroid therapies. Additionally, women using oral contraceptives or those undergoing oral treatments with specific agents against Trichomonas have reported a rising frequency of occurrence.
The composition of the treatment is standardized to provide targeted antimicrobial action. Every 4g of the cream contains 100 mg of tetracycline hydrochloride and 50 mg of amphotericin B. The formulation includes a hydrophilic neutral base, cetyl alcohol, mineral oil, methylparaben, propylparaben, sodium hydroxide, vitamin E, sodium metabisulfite, osmosis water, and tetrasodium EDTA. These additional components serve to stabilize the active pharmaceutical ingredients and ensure proper delivery of the medication.
Tetracycline Risks and Pregnancy Precautions
While the medication is applied topically and does not typically exhibit systemic action, strict precautions are necessary for certain populations. Physicians advise extreme caution during pregnancy, particularly for women with renal insufficiency.
.webp "Photo: consultaremedios.com.br")
A significant concern involves the use of tetracycline during the final stages of pregnancy and throughout the lactation period. Because tetracycline can affect the tooth coloration of a neonate, medical guidance suggests avoiding use during the third trimester and while breastfeeding. This risk occurs because tetracycline has a high affinity for calcium. When it crosses the placenta or is passed through breast milk, it can bind to the calcium in developing bones and teeth, potentially leading to permanent discoloration or enamel hypoplasia.
Patients should also be aware of potential side effects. The most common adverse reactions reported include local burning sensations and itching. Regarding contraindications for the medication, use is prohibited for individuals with known sensitivity to any of the formula’s components.
To ensure efficacy, the treatment protocol generally requires one 4g applicator to be used daily for a period of 7 to 10 days. Clinical guidelines emphasize that patients should not interrupt the treatment without consulting a physician, as stopping prematurely may hinder the complete cure of the infection. Adherence to the full prescribed duration is essential for preventing antimicrobial resistance. Stopping the application of tetracycline before the full cycle is complete may allow surviving bacteria to multiply, potentially leading to a recurrence of the infection that is more difficult to treat.
Consult your healthcare provider.
Find more reporting in our Health section.
